ORGO - Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th.

Jul 09, 2026 03:30 AM • globenewswire.com

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepted for review the Company's Biologics License Application (BLA) for ReNu®, a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis (OA).

Jul 06, 2026 12:05 PM • globenewswire.com

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges.

Jun 15, 2026 12:32 AM • seekingalpha.com

Organogenesis Q1 Earnings Call Highlights

Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare policy changes and related commentary from the Centers for Medicare & Medicaid Services (CMS).

May 08, 2026 12:07 PM • marketbeat.com

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

May 08, 2026 01:21 AM • seekingalpha.com

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026.

May 07, 2026 12:05 PM • globenewswire.com

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain

Apr 28, 2026 12:30 PM • globenewswire.com

What's Going On With Organogenesis Stock On Wednesday?

Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.

Apr 08, 2026 06:15 AM • benzinga.com

Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight

Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant results in a randomized controlled trial for diabetic foot ulcers, strengthening ORGO's clinical and commercial position. ORGO faces a 25–38% revenue decline in 2026 from CMS reimbursement changes, but RCT-backed evidence de-risks coverage and supports a recovery thesis into 2027.

Apr 07, 2026 09:01 AM • seekingalpha.com

Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win

The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.

Apr 07, 2026 04:22 AM • benzinga.com

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a randomized controlled trial (RCT) evaluating PuraPly®AM plus standard of care (SOC) versus SOC alone in the management of non-healing diabetic foot ulcers (DFUs).

Apr 06, 2026 03:02 PM • globenewswire.com

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administration (FDA) resulting in confirmation to initiate a rolling Biologics Licenses Application (BLA) for ReNu planned before the end of December.

Apr 06, 2026 01:30 PM • globenewswire.com

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th.

Apr 06, 2026 03:30 AM • globenewswire.com

SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO

SG Americas Securities LLC raised its holdings in Organogenesis (NASDAQ: ORGO) by 199.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 565,501 shares of the company's stock after buying an additional 376,623 shares during the quarter. SG Americas Securities LLC owned 0.45%

Apr 04, 2026 12:59 AM • defenseworld.net

Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript

Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript

Feb 26, 2026 06:57 PM • seekingalpha.com

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025.

Feb 26, 2026 11:05 AM • globenewswire.com

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th.

Feb 19, 2026 11:05 AM • globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Feb 03, 2026 09:05 AM • globenewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jan 29, 2026 05:00 AM • prnewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jan 22, 2026 05:00 AM • prnewswire.com (Hide legal announcements)

Organogenesis initiated with a Hold at Truist

$3.00 (was $2.66)

UBS

May 28, 2026 06:13 AM • TheFly

Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold

$3.00 (was $2.66)

Ravi Misra · Truist Financial

May 28, 2026 06:06 AM • StreetInsider

Organogenesis price target raised to $9 from $7 at BTIG

$9.00 (was $5.14)

BTIG

Nov 20, 2025 07:10 AM • TheFly

Organogenesis price target raised to $6 from $4 at Morgan Stanley

$6.00 (was $6.01)

Morgan Stanley

Mar 05, 2025 07:21 AM • TheFly

Organogenesis initiated with a Buy at Lake Street

$5.00 (was $2.64)

Brooks O'Neil · Lake Street

Jun 28, 2024 04:01 AM • TheFly